STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On March12, 2018, Strongbridge Biopharma plc (the “Company”) issued a press release reporting fourth quarter and year-end 2017 financial results and providing a corporate update. A copy of the press release is attached to this Current Report on Form8-K as Exhibit99.1.
The information contained in this Current Report on Form8-K and Exhibit99.1 is being furnished to the Commission and shall not be deemed “filed” for the purpose of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form8-K and Exhibit99.1 shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended.
Item 7.01 Regulation FD.
The response to Item 2.02 is incorporated herein by reference to this Item 7.01.
Item 9.01 Financial Statements and Exhibits.
Strongbridge Biopharma plc ExhibitEX-99.1 2 a18-8017_1ex99d1.htm EX-99.1 Exhibit 99.1 Strongbridge Biopharma plc Reports Full-Year 2017 Financial Results ~ KEVEYIS® (dichlorphenamide) Fourth Quarter and Full-Year 2017 Revenue of $3.0 Million and $7.0 Million,…To view the full exhibit click
About STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP)
Strongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases. Its principal focus is to build its rare endocrine franchise, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly. Its product candidate, COR-003 (levoketoconazole), is a cortisol synthesis inhibitor, indicated for the treatment of endogenous Cushing’s syndrome. It is conducting SONICS, a pivotal Phase III clinical trial for COR-003. Its product candidate, COR-005 (veldotide), is a multi-receptor targeted somatostatin analog (SSA) in Phase II clinical development for the treatment of acromegaly patients. Its product candidate also includes BP-2002.
An ad to help with our costs